The role of mTOR signaling pathway in premalignant and malignant cervical lesions

Purpose of the study: Aberrant activation of the Akt/mTOR/pS6 signaling pathway has been identified in various types of cancer and is under investigation in cervical cancer. The purpose of this study was to assess the expression of the phosphorylated/activated forms of Akt (upstream molecule), 4E-BP1 and pS6 (downstream molecules) in biopsy samples of cervical low grade squamous intraepithelial lesions (LSIL), high grade squamous intraepithelial lesions (HSIL), and squamous cell carcinoma (Ca) compared to normal cervical epithelium. Material and Methods: The study included 38 cases diagnosed as LSIL, 31 cases as HSIL, 29 cases as Ca, and eight control cases from normal cervix. Immunohistochemistry was used to assess the expression of pAkt, p4E-BP1 and pS6. Results: Statistical analysis revealed significant differences between HSIL and Ca groups compared to controls regarding intensity, positivity, and total scores for all three molecules (p < 0.001). A trend for higher expression with increasing grade of dysplasia was demonstrated. Conclusion: These results strongly support the view that the mTOR signaling pathway is involved in cervical carcinogenesis.

Cervical cancer; mTOR signaling pathway; LSIL; HSIL.

[1] Rosai J.: “Rosai and Ackerman’s surgical pathology”. 9th ed. Philadelphia: Mosby, Elsevier Inc., 2004 1532.

[2] Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., Gutkind J.S.: “Dysregulated molecular networks in head and neck carcinogenesis”. Oral Oncol., 2009, 45, 324.

[3] Gao N., Flynn D.C., Zhang Z., Zhong X.S., Walker V., Liu K.J., et al.: “G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells”. Am. J. Physiol. Cell Physiol., 2004, 287, C281.

[4] Gao N., Zhang Z., Jiang B.H., Shi X.: “Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer”. Biochem. Biophys. Res. Commun., 2003, 310, 1124.

[5] Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al.: “Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma”. J. Clin. Oncol., 2004, 22, 909.

[6] Hudes A.: “phase III, randomized, 3 arm study of temsirolinus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor risk patients with advanced renal cell carcinoma”. Proc. Am. Soc. Clin. Oncol., 2006, 24, 2S.

[7] Cassinelli G., Zuco V., Gatti L., Lanzi C., Zaffaroni N., Colombo D., Perego P.: “Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells”. Curr. Med. Chem., 2013, 20, 1923.

[8] Diaz-Padilla I, Duran I., Clarke B.A., Oza A.M.: “Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer”. Cancer Treat Rev., 2012, 38, 767.

[9] Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., et al.: “Increased expression of pAKT is associated with radiation resistance in cervical cancer”. Br. J. Cancer, 2006, 94, 1678.

[10] Faried L.S., Faried A., Kanuma T., Sano T., Nakazato T., Tamura T., et al.: “Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy”. Oncol. Rep., 2006, 16, 57.

[11] Vega F., Medeiros L.J., Leventaki V., Atwell C., Cho-Vega J.H., Tian L., et al.: “Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma”. Cancer Res., 2006, 66, 6589.

[12] Tian L., Claret F.X., Rassidakis G.Z.: “Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma”. Cancer Res., 2006, 66, 6589.

[13] Ji J., Zheng P.S.: “Activation of mTOR signaling pathway contributes to survival of cervical cancer cells”. Gynecol. Oncol., 2010, 117, 103.

[14] Feng W., Duan X., Liu J., Xiao J., Brown R.E.: “Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions”. Int. J. Clin. Exp. Pathol., 2009, 2, 249.